Metabolomic biomarkers in serum and urine in women with preeclampsia by Austdal, Marie et al.
Metabolomic Biomarkers in Serum and Urine in Women
with Preeclampsia
Marie Austdal1,2,3*, Ragnhild Bergene Skra˚stad4,5, Astrid Solberg Gundersen6, Rigmor Austgulen6,7,
Ann-Charlotte Iversen6,7, Tone Frost Bathen1,3
1Department of Circulation and Medical Imaging, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway, 2 Liaison
Committee between the Central Norway Regional Health Authority (RHA) and Norwegian University of Science and Technology (NTNU), Trondheim, Norway, 3 St. Olavs
Hospital, Trondheim University Hospital, Trondheim, Norway, 4Department of Laboratory Medicine, Children’s and Women’s Health, Faculty of Medicine, Norwegian
University of Science and Technology (NTNU), Trondheim, Norway, 5National Center for Fetal Medicine, St. Olavs Hospital, Trondheim, Norway, 6Department of Cancer
Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway, 7Centre of Molecular Inflammation
Research (CEMIR), Faculty of Medicine, NTNU, Trondheim, Norway
Abstract
Objective: To explore the potential of magnetic resonance (MR) metabolomics for study of preeclampsia, for improved
phenotyping and elucidating potential clues to etiology and pathogenesis.
Methods: Urine and serum samples from pregnant women with preeclampsia (n = 10), normal pregnancies (n = 10) and
non-pregnant women (n = 10) matched by age and gestational age were analyzed with MR spectroscopy and subjected to
multivariate analysis. Metabolites were then quantified and compared between groups.
Results: Urine and serum samples revealed clear differences between women with preeclampsia and both control groups
(normal pregnant and non-pregnant women). Nine urine metabolites were significantly different between preeclampsia and
the normal pregnant group. Urine samples from women with early onset preeclampsia clustered together in the
multivariate analysis. The preeclampsia serum spectra showed higher levels of low and very-low density lipoproteins and
lower levels of high-density lipoproteins when compared to both non-pregnant and normal pregnant women.
Conclusion: The MR determined metabolic profiles in urine and serum from women with preeclampsia are clearly different
from normal pregnant women. The observed differences represent a potential to examine mechanisms underlying different
preeclampsia phenotypes in urine and serum samples in larger studies. In addition, similarities between preeclampsia and
cardiovascular disease in metabolomics are demonstrated.
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Introduction
Preeclampsia (PE) is a complex syndrome affecting about 3% of
pregnancies [1]. It presents serious risk of both maternal and fetal
morbidity and mortality [2]. PE is characterized by high blood
pressure and proteinuria in the second half of pregnancy [3]. No
tests accurately predict the onset of PE, and implementation of
fetal delivery is the only definitive treatment for threatening
manifestations of symptoms [1].
The pathogenesis of PE is still undefined. However, it is
generally assumed that it starts in early pregnancy with poorly
developed placental vascularization, giving rise to placental
oxidative stress and imbalanced interaction between maternal
and fetal cells. Later, inappropriate and exaggerated maternal
responses to the placental stress are established, involving
endothelial activation and systemic inflammation [4]. The
inflammation in PE shows a strong similarity to the development
of cardiovascular diseases (CVD) [4], and it has been reported that
women with preeclamptic pregnancies have an up to eight-fold
increased risk of later cardiovascular events [5]. The shared
underlying mechanisms include endothelial dysfunction, metabolic
abnormalities and increased oxidative stress [6].
Metabolites are constituents of the metabolism, chemical
interactions in the body necessary for life [7]. Metabolomics is
the systematic study of metabolites in tissues and biofluids [8]. The
concentrations of metabolites and their combinations can be used
as predictive models for disease classification and progression [8].
Robust statistical methods are applied to handle the massive data
outputs.
Metabolomics analysis holds potential for detailed phenotyping
of the PE syndrome, but few metabolomics studies of women with
active disease have so far been undertaken. Studies by Turner et al.
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[9,10], using MR metabolomics on serum from women diagnosed
with PE reported metabolic patterns attributed to oxidative stress
including decreased lipid and ketone body content, and the
findings indicated that this method could be useful for PE
phenotyping. Schott et al. [11] used both proton and phosphorous
MR spectroscopy to analyze plasma from women with PE. They
found a decrease in HDL and a trend towards higher levels of
VLDL2 and LDL2 in this group compared to healthy pregnancies.
However, no metabolomics studies have analyzed both urine and
serum from the same group of women, which represents a more
comprehensive view of the metabolome. Detailed analysis of body
fluids from women with preeclampsia could improve diagnostic
accuracy and possibly predict perinatal outcomes and future risk
for the mother.
Further research is needed to establish the role of metabolomics
and the robustness of the method in preeclampsia. Furthermore, a
discussion of the discriminatory metabolites in a more biological
context relevant to PE is generally lacking. To this end, the aim of
the present study was to establish the metabolic profiles of body
fluids (urine and serum) from women with PE, normal pregnancies
and from non-pregnant women by MR metabolomics. Detailed
phenotyping of the PE syndrome and potential clues to etiology
and pathogenesis were explored.
Materials and Methods
Ethics Statement
All participating women signed informed consents and the study
was approved by the Regional Committee for Medical and Health
Research Ethics (REC), Central Norway, reference number 2011/
761.
Study Population
Women admitted with PE at the maternity ward at St. Olavs
Hospital, Trondheim University Hospital, Norway gave samples
to the study. The PE diagnosis was based on the diagnostic criteria
of the Norwegian Medical Association (blood pressure $ 140/90,
proteinuria $+1, measured at least twice four to six hours apart
after gestational week 20) [12]. Pregnant and non-pregnant
control women were recruited by appeals to environments of St.
Olavs Hospital and Røros Medical Center, Røros, Norway.
Control women with previous PE pregnancies were not included.
Gestational age for both cases and controls were based on routine
ultrasound examination between gestational week 17 and 20.
Information about health status and pregnancy was collected from
interviews and medical journals. All included women were of
Scandinavian ethnicity.
Sample Handling and Spectroscopy
Peripheral venous blood (5 mL) and spot urine samples (20 mL)
were collected from nonfasting women with PE at time of
diagnosis, from healthy pregnant women matched by age and
gestational age to the PE group, and from non-pregnant women
matched by age to the PE group. Aliquots (1.8 mL) were stored at
280uC prior to analysis.
Samples were thawed at 20uC, mixed with bacteriostatic buffer
and stored at 5uC until analysis (#15 hours). Urine was
centrifuged at 6000 RPM (Sorvall RMC 14; DuPont) for five
minutes. The supernatant (540 mL) was mixed with buffer (60 mL)
(pH 7.4 1.5 mM KH2PO4 in D2O, 0.1% Trimethyl-Silyl Propi-
onate (TSP), 2 mM NaN3) and analyzed in 5 mm NMR tubes
(Norell Inc., NJ, USA). Serum (100 mL) was mixed with buffer
(100 mL) (pH 7.4 0.075 mM Na2HPO4, 5 mM NaN3, 5 mM TSP)
and analyzed in 3 mm NMR tubes. MR analysis was performed at
the MR Core Facility at NTNU, Trondheim, Norway using a
Bruker Avance III Ultrashielded Plus 600 MHz spectrometer
(Bruker Biospin GmbH, Germany) equipped with 5 mm QCI
Cryoprobe with integrated, cooled preamplifiers for 1H, 2H and
13C. Experiments were fully automated using the SampleJetTM in
combination with Icon-NMR on TopSpin 3.1 software (Bruker
Biospin). Proton spectra were acquired using 1D NOESY with
presaturation and spoil gradients on urine samples and a 1D lipid
and water suppressing Carr-Purcell-Meiboom-Gill sequence
(CPMG) on serum samples. Diffusion edited serum spectra
(LEDBPG) for suppression of small molecular weight metabolite
signals were also acquired. Additional 2D spectra of urine samples
were acquired for metabolite identification: J-resolved spectrosco-
py (JRES), Heteronuclear Multiple Bond Correlation Spectrosco-
py (HMBC), Heteronuclear Single Quantum Coherence Spec-
troscopy (HSQC) and Total Correlation Spectroscopy (TOCSY).
Additional NMR parameters are given in Tab 3. Spectra were
Fourier transformed to 128 K after 0.3 Hz exponential line
broadening. Chemical shifts were referenced to TSP (d0 ppm).
Multivariate analysis
In MR Metabolomics, common statistical methods are Principal
Component Analysis (PCA) and Partial Least Squares Discrimi-
nant Analysis (PLS-DA) [13]. PCA is a powerful method of data
extraction, which finds combinations of variables that describe
trends in large data, called principal components (PCs), visualized
in scores and loading plots. The score plots show each spectrum as
an object in the principal component space, and are useful for
identifying clusters and outliers in the dataset. The loading plots
show the contributing variables to each PC. PLS-DA models the
relationship between the spectra and class information using
multivariate regression methods. The metabolites responsible for
the separation between classes are shown in loading variables
(LVs), and may be colored by variable importance in projection
(VIP) [13]. Multivariate analysis was performed using PLS_
Toolbox 6.7.1 (Eigenvector Research, USA).
Spectra were imported to Matlab r2012a (The Mathworks, Inc.,
MA, USA). Residual water signals were removed. The urine
NOESY spectra were normalized to equal area below the curve,
cut to region of interest (ROI) (d8–1 ppm) and peak aligned using
icoshift [14]. The serum CPMG spectra were cut to ROI (d4.5–
0.5 ppm) and aligned by referencing the left alanine peak at
d1.50 ppm. The serum LEDBPG spectrum were cut to ROI
(d1.45–0.77 ppm) containing signals from methyl and methylene
groups from lipoproteins, and normalized to equal area for
additional analysis of the lipid profile.
Spectra sets were mean centered and explored by PCA with
random subset cross validation for initial visualization of the data
and detection of inherent trends and outliers. Using PLS-DA, a
classification model was created on samples from the women with
preeclampsia and healthy pregnant groups using the number of
LVs giving the smallest classification error, and cross validated by
‘‘leave one out’’ which creates the model on all but one sample,
testing it on the remaining sample. Permutation testing with 1000
repeats (random reshuffling of classes, then creating a new
predictive model) was done to measure the significance of the
predictive model at 95% compared to a classification in arbitrary
groups.
Identification and quantification of metabolites
Metabolites were assigned using Bruker AMIX software v.2.5
(Analysis of MIXtures software, Bruker Biospin) and Chenomx
v.7.11 (Chenomx Inc., Alberta, Canada), matching spectra to
reference databases of metabolites. 2D NMR spectra (JRES,
Metabolomic Biomarkers in Preeclampsia
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COSY, HSQC, and HMBC) were reviewed to confirm assign-
ments. Additional assignments were done with help from literature
[7,15]. All identified metabolites were quantified in Chenomx,
based on the visible TSP concentration. TSP was quantified in
Topspin using the PULCON [16] principle based on a creatine
(14.43 mM) spectrum recorded at equal parameters. Serum
metabolites were quantified from CPMG spectra, and urine
metabolites from NOESY spectra. Concentrations were imported
to SPSS v. 20.0.0 (IBM Corp, NY, USA) and subjected to
Kruskal-Wallis test of three independent samples. Urine metab-
olite concentrations were analyzed as [metabolite/creatinine] ratio
to correct for dilution. The significance cutoff was set to p,0.05
after Benjamini-Hochberg correction [17] of p-value for multiple
parallel tests.
Results
Details of the study groups are given in Table 1. Ten women
with PE, ten healthy pregnant women and ten non-pregnant
women were included. Age and gestational age were matched, and
Table 1. Characteristics of study participants.
Data PE PC NP p-value
n (samples) 10 10 10 -
Age (years) 29.5 (22–39) 32.6 (28–39) 30.7 (24–39) .0.05
GA at sampling
(week)
35.9 (21.7–37.9) 35.2 (18.6–37.4) N/A .0.05
GA at onset (week) 33.2 (21.4–36.9) N/A N/A -
BP sys. (mmHg) 163 (143–174) 120(100–191) N/A 0.000
BP dia. (mmHg) 104 (96–111) 78 (60–96) N/A 0.000
Proteinuriaa 3 (1–4) 0.1 (0–1) N/A 0.000
Values are given as median (min-max). PE: Women with preeclampsia. PC:
Pregnant controls. NP: Non-pregnant controls. GA: Gestational age. BP: Blood
pressure. Dia: Diastolic. Sys: Systolic. N/A: Not applicable. Statistical p-values
computed by Kruskal-Wallis independent samples test.
aProteinuria measured with dipstick.
doi:10.1371/journal.pone.0091923.t001
Figure 1. Results from urine analysis. Results from Principal Component Analysis (PCA) and Partial Least Squares Discriminant Analysis (PLS-DA)
of urine samples from women with preeclampsia (PE, pregnant controls (PC) and non-pregnant controls (NP). A) Typical high resolution NMR
spectrum of urine from a PE subject, most abundant metabolites annotated. B) PCA score plot separating all three groups in two dimensions. C)
Loading Variables (LV) 1 and 2 of the PLS-DA used to create a model discriminating between PE and PC groups. Arrow direction indicates increased
metabolite level. D) Scores on LV1 and LV2 showing a clustering of early onset PE samples (marked by arrows). TMAO: Trimethylamine-N-Oxide.
doi:10.1371/journal.pone.0091923.g001
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in accordance with the PE diagnosis, proteinuria and blood
pressure were significantly different between the two pregnant
groups (not measured in the nonpregnant group).
Results from the urine analyses are shown in Figure 1 and
Table 2, with a typical urine spectrum shown in Figure 1A. The
urine PCA (Figure 1B) score plot shows clustering of the three
groups. PC1 separated samples from both the PE and healthy
pregnant groups from the non-pregnant group based on a
combination of higher creatinine and trimethylamine-N-oxide
(TMAO) levels, and lower glycine levels for the non-pregnant
group. PC3 separated preeclamptic women from healthy pregnant
women similarly to the subsequent PLS-DA analysis. Creatinine
levels were similar between preeclamptic and healthy pregnant
women. The PLS-DA model classified urine spectra from
preeclamptic and healthy pregnant groups with 95% accuracy
(sensitivity = 0.9 and specificity = 1.0) using two LVs (Figure 1C
and 1D) and was significant at p# 0.001. The model separated the
groups based on a combination of higher choline and creatine
levels, and lower glycine levels for preeclamptic women compared
to healthy pregnant women. Urine samples from women with
early onset PE (,34 weeks) had lower scores on LV2 than the late
onset women. (Fig 1D, starred). These had higher TMAO and
creatinine, and lower choline and creatine compared to the late
onset PE group. The urinary metabolite concentrations are shown
in Table 2. The variation in concentrations was similar to the
results from the multivariate analyses. Twenty-one metabolites
were significantly different between all three groups at p,0.05,
with nine metabolite concentrations significantly different between
women with PE and healthy pregnant women, and 15 between
healthy pregnant women and non-pregnant women. In summary,
urine sample spectra from the PE group were clearly different
from those of healthy pregnant women based on metabolite
content, and a difference in metabolic profile between women with
early and late onset PE may exist. Healthy pregnant women also
showed a different urinary metabolic profile than non-pregnant
women, with higher excretion of amino acids.
Results from the serum analyses are shown in Figure 2 and
Table 3, with a typical serum spectrum in Figure 2A. The CPMG
and LEDBPG spectra of all serum samples were explored using
PCA. A trend of metabolite profiles showing a continuous change
from non-pregnant women through healthy pregnant women to
women with PE was found, mainly based on increasing total serum
lipid content (Figure 2B). All pregnant women had higher serum
lipid content than the non-pregnant women, and women with PE
had even higher serum lipid content. The distribution of
lipoproteins was also different between groups, with the PE group
expressing higher signals originating from VLDL and LDL and
lower signals from HDL. The signals from the lipoproteins in the
NMR spectra consist of several highly overlapping peaks, arising
from the lipid moieties within the various lipoproteins. The
chemical shifts differ slightly between the particles due to the
density differences of the lipoproteins, with lower densities at
higher chemical shifts (Figure 2D) [18]. PLS-DA classified serum
CPMG spectra from women with PE and healthy pregnant
women with 90% accuracy (sensitivity = 0.8 and specificity = 1.0)
using four LVs, with heavy reliance on lipid levels for separation
between PE and PC (Figure 2C). The lipoprotein distribution was
explored further in a PLS-DA on the LEDBPG spectra, as shown
in Figure 2D. PE cases were discriminated from healthy pregnant
controls by the lipoprotein profile alone, with increased signal in
the LDL-VLDL region (the leftmost part of the lipid signal) and
decreased signal in the HDL region of the serum spectra. Visible
serum metabolites concentrations are shown in Table 3. Serum
from women with PE had significantly lower concentrations of
Table 2. Urine metabolite concentrations.
Metabolite (mM/mM
creatinine) PE PC NP p-value
Glycine*{ 2606150 4986219 138679 0.000
p-Cresol Sulfate* 6.264,3 39613 30610 0.000
Alanine{ 67657 86651 2165 0.000
Threonine{ 846102 94648 2065 0.000
Choline{ 41650 1064 5.362.7 0.004
Hippurate* 88661 2656144 2806188 0.004
Histidine*{ 1536129 2666100 79642 0.004
Asparagine*{ 31642 47624 1367 0.004
Isobutyrate*{ 2168 1367 667 0.004
Lactate{ 36627 736137 9.664.4 0.004
Citrate 2036107 4736136 3716217 0.004
Leucine{ 9.464.8 8.061.6 5.061.3 0.010
Dimethylamine* 66613 4167 40618 0.015
Trigonelline* 6.364.9 16615 29622 0.015
2-Oxoglutarate 36623 4069 13610 0.016
Ethanolamine{ 75624 66619 44612 0.018
Isoleucine{ 6.363.8 5.261.2 3.161.1 0.018
cis-Aconitate{ 37615 39612 2565 0.018
Creatine 1316118 766138 23625 0.041
Glutamine{ 114688 121637 70620 0.041
Glucose*{ 38671 75644 356 15 0.049
Valine{ 7.666.7 6.162.0 3.861.4 .0.05
Tyrosine 28619 23612 1466 .0.05
N-N-Dimethylglycine 6.064.0 5.363.0 3.361.7 .0.05
Malonate 58649 1566187 726105 .0.05
Uracil 8.063.8 10.262.8 7.163.2 .0.05
N-Phenylacetylglycinea 41629 71635 57624 .0.05
Betaine 1268 15613 8.065.2 .0.05
2-Methylglutarate 1167 1669 6.963.2 .0.05
Guanidoacetate 70677 77641 63639 .0.05
Formate 23612 35618 23613 .0.05
3-Hydroxybutyrate 9.367.9 16615 16625 .0.05
Acetate 8.565.8 1165 1269 .0.05
Urea 295761211 225161077 279561845 .0.05
2-Hydroxybutyrate 8.063.5 7.461.2 5.961.3 .0.05
Pyruvate 7.864.9 15615 6.362.1 .0.05
TMAO 67658 54654 66678 .0.05
Creatinineb 30 638 21613 26614 .0.05
o-Acetylcholine 2.163.1 1.762.1 1.460.8 .0.05
p-Methylhistidine 46655 48667 50656 .0.05
Phenylalanine 17613 1568 1465 .0.05
Values given as mean [metabolite/creatinine]6sample standard deviation. PE:
Women with preeclampsia. PC: Pregnant controls. NP: Non-pregnant controls.
TMAO: Trimethylamine-N-Oxide.
aAs suggested by Chenomx, may instead be phenylacetylglutamine.
bAbsolute creatinine concentration – not corrected for dilution.
*Significantly different metabolite concentration between PE and PC with a
cutoff value at p = 0.05 after Benjamini-Hochberg correction using the Kruskal-
Wallis test for nonparametric distributions of concentrations for three
independent groups.
{Significantly different metabolite concentration between PC and NP.
doi:10.1371/journal.pone.0091923.t002
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histidine than the healthy pregnant women, and non-significant
lower levels of formate and higher levels of glycerol. Healthy
pregnant women had higher alanine and lactate than the non-
pregnant women.
Discussion
The present study clearly demonstrates the metabolic differ-
ences between the women with PE and those with healthy
pregnancies, in both urine and in serum. The metabolomics
method additionally reveals a possible way to subgroup the disease
based on metabolic profiles. The metabolic profiles gave new
information about possible pregnancy- and disease-induced
changes.
The strength of multivariate metabolomic analysis is that the
entire visible metabolome is taken into account; and metabolites
with small and large variation contribute to the end result. As a
result there are limitations towards finding definite mechanisms
correlating to alterations in isolated metabolites. Many small
metabolites visible to MR metabolomics are involved in several
pathways, and may not be comparable between the urine and
serum metabolome.
Differences associated with normal pregnancy compared to
non-pregnant women included increased amino acids, choline,
and lactate in urine, and higher alanine and lactate in serum. A
similar pattern was found in a study by Diaz et al [19] following
healthy pregnancies with MR metabolomics on urine. The
increased excretion of amino acids is suggested to be caused by
impaired renal filtration in healthy pregnancies [19]. The choline
increase appears as a trend increasing from non-pregnant to
healthy pregnant to preeclamptic women. Although choline
metabolism appears important to fetal development [20], it is
difficult to pinpoint the exact cause of the increase. The increase of
lactate in both urine and serum from pregnant women confirms
Figure 2. Results from serum analysis. Results from Principal Component Analysis (PCA) and Partial Least Squares Discriminant Analysis (PLS-DA)
on the spectra of serum samples from women with preeclampsia (PE), pregnant controls (PC) and non-pregnant controls (NP). ppm: parts per million,
resonance frequency of metabolite. A) Typical highly resolved serum CPMG (lipids suppressed) and LEDBPG (small metabolites suppressed) spectra
from a woman with PE with some annotated metabolites. B) Scores plot and loading profile of the PCA separating CPMG spectra of the three groups.
C) Scores plot and Loading Variable (LV) 1 from the PLS-DA of CPMG spectra showing class discrimination based on lipid level, where women with PE
clearly have higher levels of total lipids in the serum compared to pregnant controls D) Score plot and LV1 of the LEDBPG showing distinction
between PE and PC groups based on lipoprotein distribution. LV1 shows higher levels of VLDL-LDL and lower levels of HDL. VLDL: very low density
lipoproteins. LDL: low density lipoproteins. HDL: high density lipoproteins.
doi:10.1371/journal.pone.0091923.g002
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the findings by other studies [19,21], and follows an increase in
prolactin linked to lactation [21].
Women with PE showed increased choline and decreased
glycine, p-cresol sulfate and hippurate in urine, which may be
related to increased oxidative stress and kidney dysfunction.
Choline and glycine are connected through the metabolic pathway
of homocysteine [22]. A previous study found elevated choline in
serum of women with preeclampsia, and connected the findings to
this pathway [20]. Reduced glycine has also been seen with
preterm birth [20]. Urinary choline increase has been associated
with fetal stress in the second trimester [23]. Glycine is a precursor
to glutathione, a tripeptide important for protection against
oxidative stress [20]. The decrease in glycine excretion in women
with PE could be a result of increased demand for glutathione in
response to oxidative stress. p-Cresol sulfate is retained in patients
with kidney damage [24], and is accordingly reduced in the PE
group which suffers from kidney dysfunction. p-Cresol sulfate is
known to increase oxidative stress in human kidney epithelial cells
[24]. Possible consequences of retained p-cresol sulfate could be
further increased kidney damage and systemic inflammation in
women with PE, thus contributing to the severity of the disease.
Hippurate is a metabolic conjugate of glycine, and may be reduced
as a consequence of reduced glycine in PE. A relation between
hippurate excretion and PE has not been reported previously. The
multivariate analysis grouped the urine samples from women with
early onset PE together, indicating a similarity in their metabolic
profile compared with women with late onset PE, and a difference
in phenotype between the two. Such a division was previously
found in serum samples from women in early pregnancy [25,26].
However, as there were only four women in this group the results
should be interpreted with caution and be followed up in a larger
study.
Metabolic profiles in maternal serum revealed significant
differences with regards to PE. The major difference detected
was the higher total serum lipid content and an increase of
VLDL/LDL signals for the PE group. Women with PE also had
higher histidine and glycerol levels than women with normal
pregnancies. Increased histidine levels were in accordance with the
study by Bahado-Singh et al which looked at first-trimester serum
[26]. Bolin et al [27] found disturbance in histidine metabolism,
with contrarily decreased histidine-rich glycoprotein in serum
throughout pregnancies which later develop PE. Although the
histidine contained in glycoproteins is different from the free
histidine seen in MR spectra, their metabolism may be related.
Histidine-rich glycoproteins interact with the coagulation system
and angiogenic pathway, and a decrease was found to predict PE
in Bolins study [27]. Increased glycerol was detected in the women
with PE, similar to the Bahado-Singh study [26], where it was
attributed to abnormal lipid metabolism as it forms the backbone
of triglycerides. The lipoprotein profiles here shown related to PE
are similar to those found for people at risk of CVD [28], with
increased low density lipoprotein levels. Lipid dysfunction starts
early in pregnancies destined for PE development [28], suggesting
that metabolomics may be used to predict the onset of PE. An
increase in low- and very-low density lipoprotein has been
recorded in patients with CVD and PE previously [28],
underscoring the similarities between the two diseases.
The quantification of serum metabolites was done on T2-edited
CPMG spectra, where lipid signals are attenuated. Therefore the
concentrations of metabolites in serum are not absolute, but
comparable between spectra. The multivariate analysis performed
on the LEDBPG spectra, where small molecular weight metabolite
signals are filtered out, showed that the lipid profile itself was
sufficient to distinguish between the two groups.
The study contains relatively few samples, limiting a complete
validation procedure. However, a rigorous cross validation was
Table 3. Serum metabolite concentrations.
Metabolite (mM) PE PC NP p-value
Histidine* 90626 72621 57612 0.036
Formate 1964 2564 2262 0.059
Glycerol 146637 105634 92629 0.059
Alanine{ 251639 303682 223631 0.059
Lactate{ 9076306 10946252 7746179 0.094
Creatine 42614 3067 3567 .0.05
Glucose 24556623 30056656 29226466 .0.05
Glycine 135631 142620 176652 .0.05
Valine 132626 155631 161626 .0.05
Acetate 2264 2669 32616 .0.05
Citrate 81618 70619 63613 .0.05
Phenylalanine 3867 37610 3464 .0.05
Glutamine 366695 375681 410660 .0.05
3-Hydroxybutyrate 80658 47613 51634 .0.05
Tyrosine 3468 3968 39610 .0.05
Glutamate 94628 106635 95637 .0.05
Creatinine 5466 5067 5367 .0.05
Leucine 116618 114628 109625 .0.05
2-Methylglutarate 1163 1262 1164 .0.05
Values given as mean6SD. PE: Women with preeclampsia. PC: Pregnant
controls. NP: Non-pregnant controls.
*Significantly different metabolite concentration between PE and PC with a
cutoff value at p = 0.05 after Benjamini-Hochberg correction using the Kruskal-
Wallis test for nonparametric distributions of concentrations for three
independent groups.
{Significantly different metabolite concentration between PC and NP.
doi:10.1371/journal.pone.0091923.t003
Table 4. PLS-DA Classification of samples as healthy pregnant or from women with preeclampsia.
Input LVs Classification accuracy Sensitivity Specificity AUC p
Urine spectra 2 95% 0.9 1 0.90 0.001
Serum CPMG spectra 4 90% 0.8 1 0.86 0.002
Serum LEDBPG spectra 4 90% 1 0.8 0.70 0.001
The sensitivity is for detecting a preeclampsia sample using Partial Least Squares Discriminant Analysis. Classification accuracy, sensitivity and specificity are from the
leave-one-out cross validation. The p-value is from permutation testing the model with 1000 repeats. LVs: number of loading variables in model. AUC: Area under the
Receiver Operator Characteristic curve. CPMG: Lipid-suppressed. LEDBPG: Low molecular weight metabolite suppressed.
doi:10.1371/journal.pone.0091923.t004
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performed to ensure that the model was valid also for samples not
included in the building of the model. As this is an exploratory
study highlighting main differences between groups, cross valida-
tion in combination with permutation testing is sufficient to
conclude whether there is a difference between groups. Analysis of
spectra using PLS-DA is prone to overfitting. However, permu-
tation testing of the urine and serum PLS-DA models (Table 4)
revealed them to be significantly different (p,0.05) from models
made on random classifications. This indicates that the spectra
contained sufficient information to distinguish between samples
from women with PE and healthy pregnant women.
The metabolic changes found in cases compared to controls
reflect the disease state of the individual. However, it is possible
that some of the changes may be evident in the metabolome before
the onset of the disease. This possibility must be evaluated in
longitudinal studies following women earlier in their pregnancies.
Urine and serum from women with PE, normal pregnancies
and non-pregnant women were effectively discriminated by MR
metabolomics. Differences were observed related to disease
processes and phenotypes. Samples from healthy pregnancies
were clearly different from samples collected from non-pregnant
women. The observed data suggest that an enlarged study is
recommended to find predictive biomarkers earlier in pregnancy
or to sub-phenotype the disease, and to investigate the association
to later cardiovascular symptoms.
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